Devon shedlock poseida
WebLinked companies : Poseida Therapeutics, Inc. Summary. Devon J. Shedlock is Chief Scientific Officer-Cell Therapies at Poseida Therapeutics, Inc. He received an undergraduate degree from Ursinus College and a doctorate from the University of Pennsylvania. Current positions of Devon J. Shedlock. WebIn addition, Dr. Devon Shedlock, Senior Vice President, Research & Development at Poseida, has invented a technology that we call the booster molecule, which uniquely allows Poseida to maintain the Tscm cells in our fully allogeneic products, while expanding the cells to create hundreds of doses from a single manufacturing run from a single ...
Devon shedlock poseida
Did you know?
WebOct 13, 2024 · SAN DIEGO, Oct. 13, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. , (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership … WebNov 9, 2024 · "We are pleased to share preclinical data for P-BCMA-ALLO1 and P-MUC1C-ALLO1, our first fully allogeneic candidates," said Devon Shedlock, Ph.D., Chief Scientific Officer, Cell Therapies at Poseida Therapeutics. "The results being shared at SITC not only demonstrate potent antitumor efficacy in preclinical models for our allogeneic …
WebDevon J. Shedlock's 20 research works with 282 citations and 1,878 reads, including: 46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for ... WebWe are thrilled to partner with Roche using Poseida’s unique allogeneic approach to develop novel CAR-T product candidates. With our proprietary technologies… 10 comments on LinkedIn
WebDevin Shedlock is on Facebook. Join Facebook to connect with Devin Shedlock and others you may know. Facebook gives people the power to share and makes the world more … WebDevon J. Shedlock's 20 research works with 282 citations and 1,878 reads, including: 46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, …
WebOct 13, 2024 · Joining Poseida as its first employee in 2015, Dr. Shedlock was most recently Senior Vice President of Research & Development, serving as a key scientific contributor in the application of the ...
WebChief Scientific Officer, Cell Therapy. Dr. Shedlock is our Chief Scientific Officer, Cell Therapy, after joining Poseida as our first employee in 2015 and most recently serving as Senior Vice President of Research & … dentist charged with poisoning wifeWebCheck out professional insights posted by Devon J Shedlock, Chief Scientific Officer at Poseida Therapeutics, Inc. ffxiv new flower vasesWebDr. Shedlock is Chief Scientific Officer, Cell Therapy at Poseida, after joining the Company as its first employee in 2015 and most recently serving as Senior Vice President of … ffxiv neverland twitterWebNov 9, 2024 · "We are pleased to share preclinical data for P-BCMA-ALLO1 and P-MUC1C-ALLO1, our first fully allogeneic candidates," said Devon Shedlock, Ph.D., Chief Scientific Officer, Cell Therapies at Poseida Therapeutics."The results being shared at SITC not only demonstrate potent antitumor efficacy in preclinical models for our allogeneic product … ffxiv newest patchWebMar 3, 2024 · Devon Shedlock joined Poseida Therapeutics in 2015. Devon served as Vice President, Preclinical Development and Senior Vice President and Head of R&D for Poseida Therapeutics. Devon Shedlock is currently Chief Scientific Officer, Cell Therapies at Poseida Therapeutics - View - Poseida Therapeutics org chart. Create your alert to … ffxiv new classes 2016WebFeb 23, 2024 · Devon Shedlock, Ph.D., Poseida's Chief Scientific Officer of Cell Therapy, is presenting on the Company's allogeneic CAR-T platform, including preclinical findings from P-BCMA-ALLO1 and P-MUC1C-ALLO1, and will discuss the benefits of taking a dual CAR approach with the Company's P-CD19CD20-ALLO1 program as an example, ... ffxiv new custom deliveriesWebHeading up the immuno-oncology research effort for Poseida at JLABS is Devon Shedlock, Ph.D., current Director of Immuno-Oncology at Poseida and the former Associate Director of the T-Cell Engineering Core that is part of Carl June's group at the University of Pennsylvania. ... Poseida is a therapeutics-focused biotechnology company … ffxiv new dc